Message From CSO & R&D President
 
Disease Areas of Focus
 
Overview
Cancer
Atherosclerosis/ Thrombosis
Diabetes
Obesity
Psychiatric Disorders
Alzheimer's Disease
Hepatitis
HIV/AIDS
Rheumatoid Arthritis
Solid Organ Transplant Rejection
 
Recent Accomplishments
 
Pipeline
 
Biologics
 
R&D Facts
 
Clinical Trials Disclosure

 

  » BMS.com Home » Pharmaceutical Research & Development » Disease Areas of Focus » Alzheimer's Disease
SEARCH INDEX
 

Pharmaceutical Research & Development


Disease Areas of Focus

Alzheimer’s Disease

Alzheimer’s Disease, a form of dementia, is a progressive brain disease that destroys memory, thinking skills, and, eventually, the ability to carry out simple tasks. Approximately 4.5 million people in the United States have Alzheimer’s. The disease usually begins after age 60, and risk increases with age. About five percent of men and women ages 65 to 74 have Alzheimer’s, and nearly half of people age 85 and older may have it. The incidence is expected to increase dramatically as life expectancy increases.1

Alzheimer’s Disease is not a normal aspect of aging.1 Thus, scientists are working to determine the causes as well as the best treatments. At present, no treatment can stop the progression of the disease. Yet for some people in the early and middle stages, various drugs may help prevent some symptoms from becoming worse for a limited time.1 Because Alzheimer represents a very significant unmet medical need, Bristol-Myers Squibb is conducting research on this highly debilitating and increasingly common disease.

Back to Disease Areas

 

1. “Alzheimer’s Disease Fact Sheet,” The National Institute on Aging of the National Institutes of Health, July 2006.




[Top Page] [Search] [Index] [Contact] [Home]

Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.

© 1999-2008 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.